ArticleToxicological research2025
Toxicity of diclofenac sodium salt after two weeks of daily intramuscular administration in cynomolgus monkeys.
Article in Toxicological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diclofenac sodium salt (DSS) has been extensively studied in pharmacological research to better understand its pain relief and inflammation-reducing properties. However, it is crucial to evaluate the safety profile of this non-steroidal anti-inflammatory drug, particularly in nonhuman primates (NHPs), such as cynomolgus monkeys. Understanding the potential adverse effects and toxicity of DSS in NHP is critical for determining their overall safety and use in clinical settings. Further investigation into its toxicity to NHPs would provide valuable information for developing and using this drug in medical practice. Our aim was to evaluate the toxicity of DSS administered repeatedly to cynomolgus monkeys to identify its safety profile in NHPs. The general toxicity of DSS was established using a 2-week repeated-dose toxicity test. Twenty-four cynomolgus monkeys were intramuscularly injected with 0, 0.33, 1, and 3 mg/kg of DSS each day. This study assessed the potential adverse effects and toxicity of DSS in these monkeys, providing valuable data for understanding its safety in clinical settings. The 2-week repeated-dose toxicity study of DSS revealed no treatment-related changes in body weight, food consumption, ophthalmology, or general symptoms. Furthermore, no significant changes were observed in hematological, clinical chemistry, or urinalysis data. Histopathological examination revealed decreased cellularity (lymphocytes) in both the thymus and spleen (white pulp). The sternal bone marrow had a higher cell count than usual. Furthermore, mixed cell and mononuclear cell infiltration, inflammation, myofiber degeneration, and muscle fiber necrosis were observed at the injection site (skin), but these findings were not considered adverse effects. Notably, the no observed adverse effect level of DSS was estimated to be greater than 3 mg/kg in both males and females. Therefore, this study established a non-toxic dose of DSS, laying the groundwork for further nonclinical studies to assess the safety of DSS using NHP. Supplementary Information: The online version contains supplementary material available at 10.1007/s43188-025-00281-4.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.